Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

PICAROS - Acalabrutinib RWE su 1L CLL in Spagna (PICAROS)

3 novembre 2026 aggiornato da: AstraZeneca

Studio di coorte non interventistico su pazienti precedentemente non trattati o intolleranti al BTKi di prima generazione con leucemia linfatica cronica che descrive l'uso di prima linea di Acalabrutinib e i suoi risultati nel mondo reale in Spagna: lo studio PICAROS

This is a multicenter non-interventional study (NIS) of patients with CLL treated with first-line acalabrutinib according to routine clinical practice in Spain. It included an initial cohort of patients who initiated treat-to-progression acalabrutinib for the first time within the year before the first site initiation visit, both for previously untreated CLL and after switching in first line from another BTK inhibitor due to intolerance in absence of progression (cohort 1). This cohort is complemented with the addition of another regarding the first-line fixed-duration acalabrutinib use with venetoclax in routine practice (cohort 2).

Panoramica dello studio

Stato

Reclutamento

Condizioni

Descrizione dettagliata

This is a multicenter, non-interventional study (NIS) based on ambispective (including retrospective and/or prospective) real-world data collection of patients with CLL who received treatment with acalabrutinib for the first time in Spain.

It included an initial cohort of patients who initiated treat-to-progression acalabrutinib for the first time within the year before the first site initiation visit, both for previously untreated CLL and after switching in first line from another BTK inhibitor due to intolerance in absence of progression (cohort 1). This cohort is complemented with the addition of another regarding the first-line fixed-duration acalabrutinib use with venetoclax in routine practice (cohort 2).

For the cohort 1, the start of acalabrutinib treatment (index date) was prior to the first site initiation visit. For both cohorts 1 and 2, the clinical decision of starting patient on acalabrutinib has to independently occur prior to the patient inclusion into this study. Patients' eligibility for study inclusion is regardless of their current status of acalabrutinib therapy, for example, patients already deceased or discontinued therapy are still eligible to be included into this study. Patient data will be collected both retrospectively and/or prospectively up to approximately 32 months from the first site initiation visit for cohort 1, and approximately 25 months after the inclusion of the last patient in the cohort 2. For patients who received acalabrutinib therapy and have deceased, only retrospective medical chart review will be conducted.

Tipo di studio

Osservativo

Iscrizione (Stimato)

315

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Andalusia
      • Almería, Andalusia, Spagna, 4009
        • Reclutamento
        • Research Site
      • Córdoba, Andalusia, Spagna, 14004
        • Reclutamento
        • Research Site
      • Granada, Andalusia, Spagna, 18014
        • Reclutamento
        • Research Site
      • Jaén, Andalusia, Spagna, 23007
        • Attivo, non reclutante
        • Research Site
      • Marbella, Andalusia, Spagna, 29603
        • Attivo, non reclutante
        • Research Site
      • Málaga, Andalusia, Spagna, 29010
        • Attivo, non reclutante
        • Research Site
      • Seville, Andalusia, Spagna, 41013
        • Reclutamento
        • Research Site
    • Aragon
      • Zaragoza, Aragon, Spagna, 50009
        • Reclutamento
        • Research Site
      • Zaragoza, Aragon, Spagna, 50009
        • Attivo, non reclutante
        • Research Site
    • Balearic Islands
      • Palma de Mallorca, Balearic Islands, Spagna, 7010
        • Attivo, non reclutante
        • Research Site
      • Palma de Mallorca, Balearic Islands, Spagna, 7198
        • Attivo, non reclutante
        • Research Site
    • Basque Country
      • Donostia / San Sebastian, Basque Country, Spagna, 20014
        • Ritirato
        • Research Site
      • Galdakao, Basque Country, Spagna, 48960
        • Ritirato
        • Research Site
    • Canary Islands
      • Las Palmas de Gran Canaria, Canary Islands, Spagna, 35016
        • Attivo, non reclutante
        • Research Site
      • Las Palmas de Gran Canaria, Canary Islands, Spagna, 35019
        • Attivo, non reclutante
        • Research Site
      • San Cristóbal de La Laguna, Canary Islands, Spagna, 38320
        • Reclutamento
        • Research Site
    • Cantabria
      • Santander, Cantabria, Spagna, 39008
        • Attivo, non reclutante
        • Research Site
    • Castille and León
      • Salamanca, Castille and León, Spagna, 37007
        • Attivo, non reclutante
        • Research Site
      • Segovia, Castille and León, Spagna, 40002
        • Attivo, non reclutante
        • Research Site
      • Valladolid, Castille and León, Spagna, 47003
        • Attivo, non reclutante
        • Research Site
      • Valladolid, Castille and León, Spagna, 47012
        • Attivo, non reclutante
        • Research Site
    • Castille-La Mancha
      • Guadalajara, Castille-La Mancha, Spagna, 19002
        • Reclutamento
        • Research Site
      • Toledo, Castille-La Mancha, Spagna, 45004
        • Attivo, non reclutante
        • Research Site
    • Catalonia
      • Barcelona, Catalonia, Spagna, 8003
        • Attivo, non reclutante
        • Research Site
      • Barcelona, Catalonia, Spagna, 8025
        • Attivo, non reclutante
        • Research Site
      • Barcelona, Catalonia, Spagna, 8035
        • Attivo, non reclutante
        • Research Site
      • Barcelona, Catalonia, Spagna, 8036
        • Attivo, non reclutante
        • Research Site
      • Granollers, Catalonia, Spagna, 8402
        • Attivo, non reclutante
        • Research Site
      • L'Hospitalet de Llobregat, Catalonia, Spagna, 8908
        • Attivo, non reclutante
        • Research Site
      • Lleida, Catalonia, Spagna, 25198
        • Attivo, non reclutante
        • Research Site
      • Terrassa, Catalonia, Spagna, 8221
        • Attivo, non reclutante
        • Research Site
    • Galicia
      • Ourense, Galicia, Spagna, 32005
        • Reclutamento
        • Research Site
      • Santiago de Compostela, Galicia, Spagna, 15706
        • Attivo, non reclutante
        • Research Site
      • Vigo, Galicia, Spagna, 36312
        • Reclutamento
        • Research Site
    • Madrid
      • Madrid, Madrid, Spagna, 28006
        • Reclutamento
        • Research Site
      • Madrid, Madrid, Spagna, 28031
        • Attivo, non reclutante
        • Research Site
      • Madrid, Madrid, Spagna, 28034
        • Attivo, non reclutante
        • Research Site
      • Madrid, Madrid, Spagna, 28905
        • Attivo, non reclutante
        • Research Site
      • Madrid, Madrid, Spagna, 28911
        • Attivo, non reclutante
        • Research Site
      • Madrid, Madrid, Spagna, 28040
        • Reclutamento
        • Research Site
      • Madrid, Madrid, Spagna, 28041
        • Reclutamento
        • Research Site
      • Madrid, Madrid, Spagna, 28046
        • Reclutamento
        • Research Site
      • Majadahonda, Madrid, Spagna, 28222
        • Attivo, non reclutante
        • Research Site
    • Murcia
      • El Palmar, Murcia, Spagna, 30120
        • Attivo, non reclutante
        • Research Site
      • Murcia, Murcia, Spagna, 30008
        • Reclutamento
        • Research Site
    • Principality of Asturias
      • Oviedo, Principality of Asturias, Spagna, 33011
        • Attivo, non reclutante
        • Research Site
    • Valencia
      • Alicante, Valencia, Spagna, 3010
        • Reclutamento
        • Research Site
      • Valencia, Valencia, Spagna, 46010
        • Attivo, non reclutante
        • Research Site
      • Valencia, Valencia, Spagna, 46014
        • Attivo, non reclutante
        • Research Site
      • Valencia, Valencia, Spagna, 46026
        • Attivo, non reclutante
        • Research Site

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

The study aims to include approximately 315 patients in the cohort 1 and 103 patients in the cohort 2 who started acalabrutinib for the first time for the treatment of their CLL. To minimize selection biases, all patients (alive or deceased) identified on acalabrutinib will be eligible for inclusion into the study. These patients will be included from approximately 50 hospitals distributed throughout Spain.

Descrizione

Inclusion Criteria:

  • Age ≥18 years old at starting acalabrutinib treatment.
  • Diagnosis of CLL.
  • Start of acalabrutinib treatment (index date) as per the CLL SmPC:
  • in treatment-naïve CLL patients or those switching in first-line between first-generation BTK inhibitor to acalabrutinib due to intolerance in absence of progression according to routine clinical practice within the year before the first site initiation visit (cohort 1).
  • in treatment-naïve CLL patients for the fixed-duration treatment combination of acalabrutinib plus venetoclax (with or without obinutuzumab) according to routine clinical practice from the EMA approval (i.e., 2 June 2025) (cohort 2).

Decision to administer acalabrutinib must be made and documented prior to inclusion into the study and must follow local clinical practice.

  • Informed consent (for alive patients).

Exclusion Criteria:

  • Enrolled in any clinical trial during acalabrutinib treatment.
  • Patients who are unable to understand the study and its questionnaires due to insufficient knowledge of the Spanish language or their health status.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: OTHER

Coorti e interventi

Gruppo / Coorte
Cohort 1

Patients who initiated treat-to-progression acalabrutinib for the first time within the year before the first site initiation visit as per routine clinical practice, both for previously untreated CLL and after switching in first line from another BTK inhibitor due to intolerance in absence of progression.

Cohort 2

Patients with first-line fixed-duration acalabrutinib use with venetoclax in routine clinical practice.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Proportion of patients on acalabrutinib therapy at 24 months after treatment initiation (cohort 1).
Lasso di tempo: 24 months after treatment initiation (cohort 1).

Proportion of patients on acalabrutinib therapy at 24 months after treatment initiation (cohort 1).

In addition to this outcome measured in the overall cohort, it will also be assessed by the following factors:

  1. the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression),
  2. presence/absence of risk factors (i.e., del17p, TP53 mutation, and unmutated IGHV).
  3. cardiovascular comorbidities (yes/no).
24 months after treatment initiation (cohort 1).
Real-world overall response rate (rwORR) achieved until the end of the observational period for first-line fixed duration acalabrutinib therapy (cohort 2)
Lasso di tempo: From fixed-duration acalabrutinib start to the start date of a subsequent line therapy or study end date (cohort 2), assessed up to 25 months after the inclusion of the last patient in the cohort 2.

rwORR (i.e., the proportion of patients that achieved complete or partial response) achieved until the end of the observational period for first-line fixed-duration acalabrutinib therapy as assessed by the treating physician (cohort 2). Complete response may include complete response, complete response with incomplete marrow recovery, or unconfirmed complete response (marrow biopsy not performed). Partial response may include partial response, or partial response with lymphocytosis. The rwORR will be assessed by the treating physician in routine clinical practice, including the use or not of the 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria. The end of observational period for first-line fixed-duration combinations of acalabrutinib is defined as the start date of a subsequent line therapy or study end date, whichever comes first.

From fixed-duration acalabrutinib start to the start date of a subsequent line therapy or study end date (cohort 2), assessed up to 25 months after the inclusion of the last patient in the cohort 2.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Acalabrutinib±venetoclax doses (cohorts 1 and 2).
Lasso di tempo: At start date and subsequent dose adjustments during acalabrutinib±venetoclax administration assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

Acalabrutinib±venetoclax doses (e.g., starting does and dose adjustments), overall (cohorts 1 and 2) and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

In cohort 2, doses (e.g., starting dose, dose adjustments, maximum dose achieved) and reasons for changes within the acalabrutinib±venetoclax fixed-duration regimen will also be described globally and for each drug separately, as well as the time to reach the maximal dose.

At start date and subsequent dose adjustments during acalabrutinib±venetoclax administration assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
Patients with acalabrutinib±venetoclax dose adjustments (n, %), temporary interruptions (n, %), and permanent discontinuations (n, %) (cohorts 1 and 2).
Lasso di tempo: From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

Acalabrutinib±venetoclax dose adjustments, temporary interruptions, and permanent discontinuations, overall (cohorts 1 and 2) and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

In patients with regimen modifications within cohort 2, the proportion of patients with these regimen modifications and the time from treatment initiation to the regimen modification within same line therapy prior to progression (e.g., treatment duration and number of cycles prior to the modification, and reason for the modification). In cohort 2, temporary interruptions, permanent discontinuations, and their reasons for changes within the acalabrutinib±venetoclax fixed-duration regimen will also be described globally and for each drug separately, as well as the proportion of patients requiring dose reductions after achieving maximum dose.

From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
Treatment duration in months (cohorts 1 and 2).
Lasso di tempo: From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

Treatment duration (cohorts 1 and 2), overall and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

In cohort 2, also median number of completed cycles and the proportion of patients who complete 14 cycles.

Baseline patient characteristics associated with treatment duration in multivariate analyses, overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

From acalabrutinib±venetoclax start to acalabrutinib±venetoclax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
Treatment adherence according to the percentage of days covered (PDC) while receiving acalabrutinib (cohort 1).
Lasso di tempo: From acalabrutinib start to acalabrutinib end, assessed up to 32 months of prospective study follow-up (cohort 1).

Treatment adherence according to the percentage of days covered (PDC) while receiving acalabrutinib, overall and by the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1).

The PDC will be based on data available on acalabrutinib treatment in pharmacy records, and defined as the percentage of days a patient has the medication available in a given period of time:

PDC (%)=(No.days covered)/(No.days of interest)×100

From acalabrutinib start to acalabrutinib end, assessed up to 32 months of prospective study follow-up (cohort 1).
TTNT (i.e., the time from the date of first dose of acalabrutinib to the first dose of the next treatment for CLL, or death from any cause) (cohorts 1 and 2).
Lasso di tempo: From the date of first dose of acalabrutinib to first dose of next CLL treatment or death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

TTNT (i.e., the time from the date of first dose of acalabrutinib to the first dose of the next treatment for CLL, or death from any cause [i.e. deaths are not censored]), overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

From the date of first dose of acalabrutinib to first dose of next CLL treatment or death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
OS (i.e., the time from the date of first dose of acalabrutinib to death from any cause) (cohorts 1 and 2).
Lasso di tempo: From the date of first dose of acalabrutinib to death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

OS (i.e., the time from the date of first dose of acalabrutinib to death from any cause), overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

From the date of first dose of acalabrutinib to death, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.
Adverse events that lead to acalabrutinib±venetoclax dose changes, temporary interruptions, or permanent discontinuation; that are considered serious during acalabrutinib±venetoclax treatment; and events of clinical interest (cohorts 1 and 2).
Lasso di tempo: From acalabrutinib±venetoclax start to acalabrutinib±venetoxlax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

Adverse events that lead to acalabrutinib±venetoclax dose changes, temporary interruptions, or permanent discontinuation.

Adverse events that are considered serious (including fatal events) during acalabrutinib±venetoclax treatment, globally and treatment related (when available).

Events of clinical interest (atrial fibrillation, hypertension, bleeding, infections, ventricular arrhythmias, hepatotoxicity, secondary primary malignancies, cytopenia, and pneumonitis) during acalabrutinib treatment, globally and treatment related (when available).

They will be described overall (cohorts 1 and 2) and according to the reason for treatment initiation (i.e., first-line treatment-naïve patients, and those switching due to intolerance in absence of progression) (cohort 1 only).

From acalabrutinib±venetoclax start to acalabrutinib±venetoxlax end, assessed up to 32 months of prospective study follow-up in the cohort 1 and 25 months after the inclusion of the last patient in the cohort 2.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

11 luglio 2023

Completamento primario (Stimato)

31 marzo 2029

Completamento dello studio (Stimato)

31 marzo 2029

Date di iscrizione allo studio

Primo inviato

29 giugno 2023

Primo inviato che soddisfa i criteri di controllo qualità

10 agosto 2023

Primo Inserito (Effettivo)

21 agosto 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

4 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

3 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • D8221R00003

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Periodo di condivisione IPD

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Criteri di accesso alla condivisione IPD

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .